A share price of Cellebrite DI Ltd [CLBT] is currently trading at $24.17, up 5.09%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CLBT shares have gain 4.45% over the last week, with a monthly amount glided 7.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cellebrite DI Ltd [NASDAQ: CLBT] stock has seen the most recent analyst activity on March 28, 2024, when Needham reiterated its Buy rating and also boosted its price target to $13.50 from $13. Previously, William Blair upgraded its rating to Outperform on March 13, 2024. On February 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $12 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $11 on July 19, 2023. William Blair downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to Neutral for this stock on August 12, 2022, and downed its price target to $6. In a note dated February 24, 2022, JP Morgan initiated an Overweight rating and provided a target price of $10.50 on this stock.
Cellebrite DI Ltd experienced fluctuations in its stock price throughout the past year between $8.91 and $24.18. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Cellebrite DI Ltd [NASDAQ: CLBT] shares were valued at $24.17 at the most recent close of the market. An investor can expect a potential drop of -17.25% based on the average CLBT price forecast.
Analyzing the CLBT fundamentals
Trailing Twelve Months sales for Cellebrite DI Ltd [NASDAQ:CLBT] were 385.17M which represents 26.94% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.15%, Pretax Profit Margin comes in at -0.8%, and Net Profit Margin reading is -0.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -4.77 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.19 points at the first support level, and at 22.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.73, and for the 2nd resistance point, it is at 25.30.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cellebrite DI Ltd [NASDAQ:CLBT] is 1.81. As well, the Quick Ratio is 1.78, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 13.06, the price to book ratio is 16.86.
Transactions by insiders
Recent insider trading involved YOSEF CARMIL, Officer, that happened on Jan 15 ’25 when 0.2 million shares were purchased. OFFICER, DAVID GEE completed a deal on Dec 27 ’24 to buy 4263.0 shares. Meanwhile, Director Aliazar Keinan bought 19385.0 shares on Dec 11 ’24.
